

极速入门

借助文献工具快速了解未知领域

主讲人 王寅


复旦大学图书馆医科馆 学科馆员

2025年3月19日

当我面对某个全新的领域



? ? ?



新手三件套



搜点文献
review/article...



写点笔记
EndNote/NE...



拼成一篇
review



就算ok了……吧？

信息收集

信息梳理

知识重构

快速入门心法



让知识的小飞轮转起来

初步知识重构

近_____年来，关于_____研究方向，全球呈现_____趋势，其中较多的论文成果来自于_____（国家/地区）。发表相关论文较多的研究机构有_____。

主要从_____等领域对相关课题进行研究，_____等领域的研究可能会带来不一样的视角。

相关的研究成果主要发表在_____等期刊上，该领域_____等几位学者的科研产出较多。

影响力较高的几篇论文分别来自于_____（国家/地区）_____（研究机构）的_____（作者）。

近半年来，_____方向引起较多关注。

可选择_____（综述文章）作为快速了解该领域的切入点。

最新的研究显示该研究方向目前发展_____。

信息 获取



十大科技信息源

- ✓ 图书
- ✓ 连续出版物
- ✓ 科技报告
- ✓ 会议文献
- ✓ 专利文献
- ✓ 标准文献
- ✓ 学位论文
- ✓ 政府出版物
- ✓ 产品样本
- ✓ 技术档案

如何选择数据库

➤ 学科前沿和关键技术：Pubmed、Embase (OVID)

➤ 医学科研评价和跟踪：Web of Science...

➤ 全文资源获取：Elsevier、Springer、Wiley、万方.....

➤ 临床决策最佳证据：BMJ BestPractice.....

➤ 临床试验注册：Cochrane Library、ClinicalTrials.gov...



Web of Science® 数据库

➤ Science Citation Index-Expanded™ (SCI-EXPANDED, 科学引文索引):

1900年-178个学科9000多种高质量学科期刊

核心合集

➤ Social Sciences Citation Index™ (SSCI, 社会科学引文索引) : 1900年-

➤ Arts & Humanities Citation Index® (A&HCI, 艺术人文引文索引) : 1975年-

➤ Conference Proceedings Citation Index™ (CPCI, 会议论文引文索引): 1990年-

➤ Derwent Innovations Index: 1966年-



从一篇新闻开始

- lenacapavir (来那卡帕韦/.....)

首创新药lenacapavir：半年注射一次的长效HIV疗法 | NEJM述评

原创 汪习成 毛霖 NEJM医学前沿 2022年05月21日 11:30 北京

lenacapavir

Clarivate

English ▾Products

Web of Science™

Search

✦ Research Assistant

Sign In ▾Register

MENU

DOCUMENTS

RESEARCHERS

Search in: Web of Science Core Collection ▾Editions: All ▾

DOCUMENTS

CITED REFERENCES

STRUCTURE

Topic ▾

Example: oil spill* mediterranean
lenacapavir

×

+ Add row

+ Add date range

Advanced search

×

 Clear

Q Search

Let Research Assistant talk you through it

Understand a topic

Literature review

Sign in to Personalize your experience

• Save searches

• Save and organize

• Manage your profile

• Get alerted when your

信息获取——检索结果获取

Clarivate

English ▾Products

Web of Science™

Search

Sign In ▾Register

MENU

Search ▸Results for lenacapavir (Topic)

225 results from Web of Science Core Collection for:

lenacapavir (Topic)

+ Add Keywords

Quick add keywords: <+ lenacapavir+ capsid inhibitor+ gs-6207+ sunlenca+ pf74+ pepfar program+ cpsf6+ dapi>

225 Documents

You may also like...

Analyze ResultsCitation ReportCreate Alert

Refine results

Export Refine

Search within results...

Quick Filters

☐🏆 Highly Cited Papers4

☐🔥 Hot Papers1

☐📄 Review Article43

☐🕒 Early Access14

☐🔒 Open Access103

☐📊 Enriched Cited Referen75

☐0/225

Add To Marked List

Export ▾

Relevance ▾

<1of 5>

☐1

📄

🔒

Lenacapavir: a first-in-class HIV-1 capsid inhibitor

Dvory-Sobol, H; Shaik, N; (...); Rhee, MS

Jan 2022 | CURRENT OPINION IN HIV AND AIDS ▾17 (1), pp.15-21

Purpose of review This review summarizes available data for lenacapavir, an investigational first-in-class agent that disrupts functioning of HIV capsid protein across multiple steps in the viral ... Show more

🕒 Free Full Text From Publisher ...

83

Citations

17

References

19?

选择?

Clarivate

English ▾Products

Web of Science™Search

Sign In ▾Register

MENU

Search > Results for lenacapavir (Topic)

225 results from Web of Science Core Collection for:

lenacapavir (Topic)

Copy query link

+ Add Keywords Quick add keywords: + lenacapavir + capsid inhibitor + gs-6207 + sunlenca + pf74 + pepfar program + cpsf6 + dapi

225 Documents You may also like... Analyze Results Citation Report Create Alert

Refine resultsExport Refine

Search within results...

Quick Filters

☐ Highly Cited Papers4

☐ Hot Papers1

☒ Review Article43

☐ Early Access14

☐ Open Access103

☐ Enriched Cited Refer75

0/225Add To Marked ListExport ▾

Relevance ▾< 1 of 5 >

1

Lenacapavir: a first-in-class HIV-1 capsid inhibitor

Dvory-Sobol, H; Shaik, N; (...); Rhee, MS

Jan 2022 | CURRENT OPINION IN HIV AND AIDS 17 (1), pp.15-21

Purpose of review This review summarizes available data for lenacapavir, an investigational first-in-class agent that disrupts functioning of HIV capsid protein across multiple steps in the viral ... Show more

Free Full Text From Publisher ...

83 Citations17 References

19?

初步知识重构——目标

近_____年来，关于_____研究方向，全球呈现_____趋势，其中较多的论文成果来自于_____（国家/地区）。发表相关论文较多的研究机构有_____。

主要从_____等领域对相关课题进行研究，_____等领域的研究可能会带来不一样的视角。

相关的研究成果主要发表在_____等期刊上，该领域_____等几位学者的科研产出较多。

影响力较高的几篇论文分别来自于_____（国家/地区）_____（研究机构）的_____（作者）。

近半年来，_____方向引起较多关注。

可选择_____（综述文章）作为快速了解该领域的切入点。

最新的研究显示该研究方向目前发展_____。

信息梳理——检索结果分析

MENU

225 Documents

You may also like...

Analyze Results

Citation Report

Create Alert

Refine results

Export Refine

Search within results...

Quick Filters

Highly Cited Papers

4

Hot Papers

1

Review Article

43

Early Access

14

Open Access

103

Enriched Cited Refer...

75

Publication Years

Show Final Publication Y...

2025

28

2024

93

2023

56

2022

32

2021

15

See all

0/225

Add To Marked List

Export

Relevance

< 1 of 5 >

1

Lenacapavir: a first-in-class HIV-1 capsid inhibitor

Dvory-Sobol, H; Shaik, N; (...); Rhee, MS

Jan 2022 | CURRENT OPINION IN HIV AND AIDS 17 (1) , pp.15-21

Purpose of review This review summarizes available data for lenacapavir, an investigational first-in-class agent that disrupts functioning of HIV capsid protein across multiple steps in the viral ... Show more

Free Full Text From Publisher

83

Citations

17

References

Related records

2

Subtypes A1 and D, and recombinant HIV-1 natural polymorphisms associated with lenacapavir drug resistance in Uganda

Omoding, D; Musinguzi, N; (...); Lee, GQ

Jan 2025 (Early Access) | JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Enriched Cited References

Background Lenacapavir, a novel HIV-1 capsid inhibitor, shows promise for treating MDR HIV-1, as well as for pre-exposure prophylaxis (PrEP) in prevention of HIV infection. Its unique mechani ... Show more

Free Full Text From Publisher

28

References

Related records

19?

信息梳理——检索结果分析

Clarivate

English ▾Products

Web of Science™

Search

Sign In ▾Register

MENU

Search ▸Results for lenacapavir (Topic)

225 results from Web of Science Core Collection for:

lenacapavir (Topic)

+ Add Keywords

Quick add keywords: <+ lenacapavir+ capsid inhibitor+ gs-6207+ sunlenca+ pf74+ pepfar program+ cpsf6+ dapi>

225 Documents

You may also like...

Analyze ResultsCitation ReportCreate Alert

Refine results

Export Refine

Search within results...

Quick Filters

☐🏆 Highly Cited Papers4

☐🔥 Hot Papers1

☐📄 Review Article43

☐🕒 Early Access14

☐🔒 Open Access103

☐📊 Enriched Cited Referen75

☐0/225

Add To Marked List

Export ▾

Relevance ▾<1of 5>

☐1

Lenacapavir: a first-in-class HIV-1 capsid inhibitor

Dvory-Sobol, H; Shaik, N; (...); Rhee, MS

Jan 2022 | CURRENT OPINION IN HIV AND AIDS ▾17 (1), pp.15-21

Purpose of review This review summarizes available data for lenacapavir, an investigational first-in-class agent that disrupts functioning of HIV capsid protein across multiple steps in the viral ... Show more

🆓 Free Full Text From Publisher ⋮

83

Citations

17

References

19?

信息梳理——检索结果分析

Clarivate

English ▾Products

Web of Science™

Search

Sign In ▾Register

>I
MENU

Search > Results for lenacapavir (To... > Analyze Results: lenacapavir (Topic)

Analyze Results

225 publications selected from Web of Science Core Collection

Web of Science Categories ▾

Sort by:Results count ▾

Show:25 ▾

Minimum record count:1

Visualization:TreeMap Chart ▾

Number of results:10 ▾

DOWNLOAD

96
Infectious Diseases

57
Pharmacology Pharmacy

20
Virology

14
Medicine
General Internal

19?

初步知识重构——目标

近_____年来，关于_____研究方向，全球呈现_____趋势，其中较多的论文成果来自于_____（**国家/地区**）。发表相关论文较多的研究机构有_____。

主要从_____等领域对相关课题进行研究，_____等领域的研究可能会带来不一样的视角。

相关的研究成果主要发表在_____等期刊上，该领域_____等几位学者的科研产出较多。

影响力较高的几篇论文分别来自于_____（国家/地区）_____（研究机构）的_____（作者）。

近半年来，_____方向引起较多关注。

可选择_____（综述文章）作为快速了解该领域的切入点。

最新的研究显示该研究方向目前发展_____。

分析检索结果——国家/地区

Clarivate

English ▾Products

Web of Science™

Search

Sign In ▾Register

>I
MENU

Search > Results for lenacapavir (To... > Analyze Results: lenacapavir (Topic)

Analyze Results

225 publications selected from Web of Science Core Collection

Countries/Regions ▾

Sort by:Results count ▾

Show:25 ▾

Minimum record count:1

Visualization:TreeMap Chart ▾

Number of results:10 ▾

DOWNLOAD

152
USA

32
ENGLAND

20
SOUTH AFRICA

15
CANADA

19?

初步知识重构——目标

近_____年来，关于_____研究方向，全球呈现_____趋势，其中较多的论文成果来自于_____（国家/地区）。发表相关论文较多的**研究机构**有_____。

主要从_____等领域对相关课题进行研究，_____等领域的研究可能会带来不一样的视角。

相关的研究成果主要发表在_____等期刊上，该领域_____等几位学者的科研产出较多。

影响力较高的几篇论文分别来自于_____（国家/地区）_____（研究机构）的_____（作者）。

近半年来，_____方向引起较多关注。

可选择_____（综述文章）作为快速了解该领域的切入点。

最新的研究显示该研究方向目前发展_____。

分析检索结果——研究机构

Clarivate

English ▾Products

Web of Science™

Search

Sign In ▾Register

>I
MENU

Search > Results for lenacapavir (To... > Analyze Results: lenacapavir (Topic)

Analyze Results

225 publications selected from Web of Science Core Collection

Affiliations ▾

Sort by: Results count ▾ Show: 25 ▾ Minimum record count: 1

Visualization: TreeMap Chart ▾ Number of results: 10 ▾

DOWNLOAD

65
GILEAD SCIENCES

22
UNIVERSITY OF CALIFORNIA
SYSTEM

14
EMORY
UNIVERSITY

14
VITA SALUTE SAN
RAFFAELE
UNIVERSITY

19?

初步知识重构

近_____年来，关于_____研究方向，全球呈现_____趋势，其中较多的论文成果来自于_____（国家/地区）。发表相关论文较多的研究机构有_____。

主要从_____等**领域**对相关课题进行研究，_____等**领域**的研究可能会带来不一样的视角。

相关的研究成果主要发表在_____等期刊上，该领域_____等几位学者的科研产出较多。

影响力较高的几篇论文分别来自于_____（国家/地区）_____（研究机构）的_____（作者）。

近半年来，_____方向引起较多关注。

可选择_____（综述文章）作为快速了解该领域的切入点。

最新的研究显示该研究方向目前发展_____。

分析检索结果——Web of Science 类别

Clarivate

English ▾Products

Web of Science™

Search

Sign In ▾Register

>I
MENU

Search > Results for lenacapavir (To... > Analyze Results: lenacapavir (Topic)

Analyze Results

225 publications selected from Web of Science Core Collection

Web of Science Categories ▾

Sort by: Results count ▾ Show: 25 ▾ Minimum record count: 1

Visualization: TreeMap Chart ▾ Number of results: 10 ▾

DOWNLOAD

96
Infectious Diseases

57
Pharmacology Pharmacy

20
Virology

14
Medicine
General Internal

19?

分析检索结果——Citation Topics 中观

Clarivate

EnglishProducts

Web of Science™

Search

Sign InRegister

>I

MENU

Search > Results for lenacapavir (To... > Analyze Results: lenacapavir (Topic)

Analyze Results

225 publications selected from Web of Science Core Collection

Citation Topics Meso

Sort by:Results count

Show:25

Minimum record count:1

Visualization:TreeMap Chart

Number of results:10

DOWNLOAD

154
1.66 Hiv

6
2.1
Synthesi

19?

分析检索结果——Citation Topics 微观

Clarivate

English ▾Products

Web of Science™

Search

Sign In ▾Register

>I
MENU

Search > Results for lenacapavir (To... > Analyze Results: lenacapavir (Topic)

Analyze Results

225 publications selected from Web of Science Core Collection

Citation Topics Micro ▾

Sort by: Results count ▾ Show: 25 ▾ Minimum record count: 1

Visualization: TreeMap Chart ▾ Number of results: 10 ▾

DOWNLOAD

96
1.66.1243 Integrase

35
1.66.11 Hiv Prevalence & Prophylaxis

15
1.66.46 Hiv-1

19?

初步知识重构

近_____年来，关于_____研究方向，全球呈现_____趋势，其中较多的论文成果来自于_____（国家/地区）。发表相关论文较多的研究机构有_____。

主要从_____等领域对相关课题进行研究，_____等领域的研究可能会带来不一样的视角。

相关的研究成果主要发表在_____等**期刊**上，该领域_____等几位学者的科研产出较多。

影响力较高的几篇论文分别来自于_____（国家/地区）_____（研究机构）的_____（作者）。

近半年来，_____方向引起较多关注。

可选择_____（综述文章）作为快速了解该领域的切入点。

最新的研究显示该研究方向目前发展_____。

分析检索结果——期刊

Clarivate

English ▾Products

Web of Science™

Search

Sign In ▾Register

>I
MENU

Search > Results for lenacapavir (To... > Analyze Results: lenacapavir (Topic)

Analyze Results

225 publications selected from Web of Science Core Collection

Publication Titles ▾

Sort by: Results count ▾ Show: 25 ▾ Minimum record count: 1

Visualization: TreeMap Chart ▾ Number of results: 10 ▾

DOWNLOAD

21
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY

9
CURRENT OPINION IN HIV AND AIDS

5
CLINICAL INFECTIOUS DISEASES

5
PHARMACOTH

19?

分析检索结果——期刊

>|

MENU

Analyze Results

225 publications selected from Web of Science Core Collection

Publication Titles

Sort by:

Results count

Show:

25

Minimum record count:

1

Visualization:

Hide Visualiza...

Number of results:

10

DOWNLOAD

Showing 25 out of 106 entries

Select All	Field:	Record Count	% of 225
☐	Publication Titles		
☐	JOURNAL OF THE INTERNATIONAL AIDS SOCIETY	21	9.333%
☐	HIV MEDICINE	18	8.000%
☐	CURRENT OPINION IN HIV AND AIDS	9	4.000%

19?

布拉福德定律 (Bradford's Law)

将一个学科的期刊分为核心区、相关区、非相关区，其数量关系满足如下公式：

核心区：相关区：非相关区 = $1:n:n^2$ (其中n为布拉福德系数)



- 各个学科领域中，少数的核心期刊汇集了绝大多数的重要信息，反映了该方向上最重要的研究成果和进展。

初步知识重构

近_____年来，关于_____研究方向，全球呈现_____趋势，其中较多的论文成果来自于_____（国家/地区）。发表相关论文较多的研究机构有_____。

主要从_____等领域对相关课题进行研究，_____等领域的研究可能会带来不一样的视角。

相关的研究成果主要发表在_____等期刊上，该领域_____等几位**学者**的科研产出较多。

影响力较高的几篇论文分别来自于_____（国家/地区）_____（研究机构）的_____（作者）。

近半年来，_____方向引起较多关注。

可选择_____（综述文章）作为快速了解该领域的切入点。

最新的研究显示该研究方向目前发展_____。

分析检索结果——学者

Clarivate

English ▾Products

Web of Science™

Search

Sign In ▾Register

>I
MENU

Search > Results for lenacapavir (To... > Analyze Results: lenacapavir (Topic)

Analyze Results

225 publications selected from Web of Science Core Collection

Authors ▾

Sort by: Results count ▾ Show: 25 ▾ Minimum record count: 1

Visualization: TreeMap Chart ▾ Number of results: 10 ▾

DOWNLOAD

25
Dvory-sobol H

17
Rhee M

14
Ogbuagu O

14
Segal-maurer S

13
Baeten J

19?

洛特卡定律 (Lotka's Law)

- 各个学科领域中，发表 n 篇论文的作者数是发表1篇论文作者的 $1/n^2$
- 一个领域发表1篇论文的作者约为60.79%



初步知识重构

近_____年来，关于_____研究方向，全球呈现_____趋势，其中较多的论文成果来自于_____（国家/地区）。发表相关论文较多的研究机构有_____。

主要从_____等领域对相关课题进行研究，_____等领域的研究可能会带来不一样的视角。

相关的研究成果主要发表在_____等期刊上，该领域_____等几位学者的科研产出较多。

影响力较高的几篇论文分别来自于_____（国家/地区）_____（研究机构）的_____（作者）。

近半年来，_____方向引起较多关注。

可选择_____（综述文章）作为快速了解该领域的切入点。

最新的研究显示该研究方向目前发展_____。

分析检索结果——高影响力论文

Clarivate

English ▾Products

Web of Science™

Search

Search ▸Results for lenacapavir (To... ▸Results for lenacapavir (Topic)

225 results from Web of Science Core Collection for:

lenacapavir (Topic)

Copy query link

+ Add Keywords

Quick add keywords:

+ lenacapavir

+ capsid inhibitor

+ gs-6207

+ sunlenca

+ pf74

+ pepfar program

+ cpsf6

+ dapi

225 DocumentsYou may also like...

Analyze ResultsCitation ReportCreate Alert

Refine results

Export Refine

Search within results...

Quick Filters

☐🏆 Highly Cited Papers4

☐🔥 Hot Papers1

☐📄 Review Article43

☐🕒 Early Access14

☐🔒 Open Access103

☐📋 Enriched Cited Referen75

☐0/225

Add To Marked List

Export ▾

Citations: highest first ▾

<1of 5>

1

🏆

Capsid Inhibition with **Lenacapavir** in Multidrug-Resistant HIV-1 Infection

Segal-Maurer, S; DeJesus, E; (...); Molina, JM

May 12 2022 | NEW ENGLAND JOURNAL OF MEDICINE ▾386 (19) , pp.1793-1803

Enriched Cited References

Background Patients with multidrug-resistant human immunodeficiency virus type 1 (HIV-1) infection have limited treatment options. **Lenacapavir**

149

Citations

19

References

19?

初步知识重构

近_____年来，关于_____研究方向，全球呈现_____趋势，其中较多的论文成果来自于_____（国家/地区）。发表相关论文较多的研究机构有_____。

主要从_____等领域对相关课题进行研究，_____等领域的研究可能会带来不一样的视角。

相关的研究成果主要发表在_____等期刊上，该领域_____等几位学者的科研产出较多。

影响力较高的几篇论文分别来自于_____（国家/地区）_____（研究机构）的_____（作者）。

近半年来，_____方向引起较多**关注**。

可选择_____（综述文章）作为快速了解该领域的切入点。

最新的研究显示该研究方向目前发展_____。

分析检索结果——最近关注

Clarivate

English ▾Products

Web of Science™

Search

Sign In ▾Register

MENU

Search ▸Results for lenacapavir (To... ▸Results for lenacapavir (To... ▸Results for lenacapavir (Topic)

225 results from Web of Science Core Collection for:

lenacapavir (Topic)

Copy query link

+ Add Keywords

Quick add keywords: <+ lenacapavir+ capsid inhibitor+ gs-6207+ sunlenca+ pf74+ pepfar program+ cpsf6+ dapi>

225 Documents

You may also like...

Analyze ResultsCitation ReportCreate Alert

Refine results

Export Refine

Search within results...

Quick Filters

☐🏆 Highly Cited Papers4

☐🔥 Hot Papers1

☐📄 Review Article43

☐🕒 Early Access14

☐🔒 Open Access103

☐📊 Ranked Cited Refer75

☐0/225

Add To Marked List

Export ▾

Usage (last 180 days): most first ▾

<1of 5>

☐1

Lenacapavir: A novel injectable HIV-1 capsid inhibitor

Hitchcock, AM; Kufel, WD; (...); Sidman, EF

Jan 2024 | INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS ▾63 (1)

Patients living with multidrug-resistant (MDR) HIV have limited antiretroviral regimen options that provide durable viral suppression. Lenacapavir is a novel first-in-class inhibitor of I ... Show more

10 Citations44 References

19?

初步知识重构

近_____年来，关于_____研究方向，全球呈现_____趋势，其中较多的论文成果来自于_____（国家/地区）。发表相关论文较多的研究机构有_____。

主要从_____等领域对相关课题进行研究，_____等领域的研究可能会带来不一样的视角。

相关的研究成果主要发表在_____等期刊上，该领域_____等几位学者的科研产出较多。

影响力较高的几篇论文分别来自于_____（国家/地区）_____（研究机构）的_____（作者）。

近半年来，_____方向引起较多关注。

可选择_____（**综述文章**）作为快速了解该领域的切入点。

最新的研究显示该研究方向目前发展_____。

分析检索结果——综述文章的选择?

Clarivate

English ▾ Products

Web of Science™

Search

Sign In ▾ Register

MENU

Search > Results for lenacapavir (To... > Results for lenacapavir (To... > Results for lenacapavir (To... > Results for lenacapavir (Topic

225 results from Web of Science Core Collection for:

lenacapavir (Topic)

Copy query link

+ Add Keywords Quick add keywords: < + lenacapavir + capsid inhibitor + gs-6207 + sunlenca + pf74 + pepfar program + cpsf6 + dapi >

225 Documents You may also like...

Analyze Results Citation Report Create Alert

Refine results Export Refine

Search within results...

Quick Filters

☐ Highly Cited Papers 4

☐ Hot Papers 1

☒ Review Article 43

☐ Early Access 14

☐ Open Access 103

☐ Enriched Cited Refer 75

0/225 Add To Marked List Export ▾ Citations: highest first ▾ < 1 of 5 >

1

Capsid Inhibition with **Lenacapavir** in Multidrug-Resistant HIV-1 Infection

Segal-Maurer, S; DeJesus, E; (...); Molina, JM

May 12 2022 | NEW ENGLAND JOURNAL OF MEDICINE 386 (19) , pp.1793-1803

Enriched Cited References

Background Patients with multidrug-resistant human immunodeficiency virus type 1 (HIV-1) infection have limited treatment options. **Lenacapavir**

149 Citations 19 References

19?

初步知识重构

近_____年来，关于_____研究方向，全球呈现_____趋势，其中较多的论文成果来自于_____（国家/地区）。发表相关论文较多的研究机构有_____。

主要从_____等领域对相关课题进行研究，_____等领域的研究可能会带来不一样的视角。

相关的研究成果主要发表在_____等期刊上，该领域_____等几位学者的科研产出较多。

影响力较高的几篇论文分别来自于_____（国家/地区）_____（研究机构）的_____（作者）。

近半年来，_____方向引起较多关注。

可选择_____（综述文章）作为快速了解该领域的切入点。

最新的研究显示该研究方向**目前发展**_____。

信息梳理

研究脉络——文献综述、图书、引文



信息梳理

√神器——HistCite(Pro)



Search > Results for lenacapavir (Topic)

225 results from Web of Science

lenacapavir (Topic)

+ Add Keywords

Quick add keywords:

+ lenacapavir

+ capsid inhibitor

225 Documents

You may also like...

Refine results

Export Refine

Search within results...

Quick Filters

☐ Highly Cited Papers 4

☐ Hot Papers 1

☐ Review Article 43

☐ Early Access 14

☐ Open Access 103

☐ Fresh Cited References 75

☐ 0/225

Add To Marked List

☐ 1

Lenacapavir: a first-in-class HIV-1 capsid inhibitor

Dvory-Sobol, H; Shaik, N; (...); Rhee, MS

Jan 2022 | CURRENT OPINION IN HIV AND AIDS 17 (1) , pp.15-21

Purpose of review This review summarizes available data for lenacapavir, an investigational first-in-class agent that disrupts functioning of HIV capsid protein across multiple steps in the viral ... [Show more](#)

Free Full Text From Publisher ...

EndNote online

EndNote desktop

Add to my researcher profile

Plain text file

RefWorks

RIS (other reference software)

BibTeX

Excel

Tab delimited file

Printable HTML file

InCites

Email

Fast 5000

More Export Options

Sign In ▾

Register

Copy query link

pepfar program

+ cpsf6

+ dapi

results

Citation Report

Create Alert

levance ▾

<

1

of 5

>

19

?

Clarivate

EnglishProducts

Web of Science™

Search

Sign InRegister

MENUMENU

Search > Results for lenacapavir (Topic)

225 results from Web of Science Core Collection for:

lenacapavir (Topic)Copy query link

+ Add KeywordsQuick add keywords: < + len+ pepfar program+ cpsf6+ dapi >

225 DocumentsYou may also like...

Refine resultsExport Refine

Search within results...

Quick Filters

☐ Highly Cited Papers4

☐ Hot Papers1

☐ Review Article43

☐ Early Access14

☐ Open Access103

0/225

1

Relevance < 1 of 5 >

83 Citations17 References

19?

Export Records to Plain Text File

Record Options

☐ All records on page

☒ Records from: 1 to 22

No more than 500 records at a time

Record Content:

Full Record and Cited References

ExportCancel

[Search >](#) [... >](#) [Results for acromegaly \(To...](#) [Results for acromegaly \(Topic\)](#)**8,543** results from Web of Science Core Collection for:[Analyze Results](#)[Citation Report](#)[🔔 Create Alert](#)🔍 **acromegaly** (Topic)

Search

[+ Add Keywords](#)

Quick add keyword

Publications

You may also like...

Refine results

Search within results...

Quick Filters

- ☐ 🏆 Highly Cited Papers
- ☐ 📄 Review Article
- ☐ ⌚ Early Access
- ☐ 🔒 Open Access

Export Records to Plain Text File

Record Options

☐ All records on page☒ Records from:

1

to

50

No more than 500 records at a time

Record Content:

Full Record and Cited References ▾

[Export](#)[Cancel](#)**500**[🔗 Copy query link](#)

< 1 of 171 >

Determinants and

17

193^{ins}

References

TIGATION 46 (7),

2,694

Pursue Bone is one of the main targets of hormones and endocrine

File

Analyses

View

Tools

Help

Untitled Collection

List of All Records

Grand Totals: LCS 230, GCS 1423, CR 8341

Collection span: 2020 - 2025

Records: 199, Author: 199, Yearly output: 199, Documents: 199

References: 5503, Words: 719

Institution | Institution with Subdivision | Country

< << < > >>

#

Date / Author / Journal

LCS GCS LCR CR

1 1 Margot N, Ram R, Rhee M, Callebaut C
Lenacapavir resistance in HIV-1 isolates
JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PHYSICIANS IN AIDS CARE. 2020 OCT; 23: 9-10

2 2 Thornhill J, Orkin C
Long-acting injectable HIV therapies: the next frontier
CURRENT OPINION IN INFECTIOUS DISEASES. 2021 FEB; 34 (1): 8-15

3 3 Margot N, Ram R, Rhee M, Callebaut C
Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Site Mutants and in Isolates with Resistance to Existing Drug Classes
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2021 MAR; 65 (3): Art. No. e02057-20

4 4 Thornhill J, Orkin C
Long-acting injectable HIV therapies: the next frontier: Republication
CURRENT OPINION IN HIV AND AIDS. 2021 MAR; 16 (2): 98-105

5 5 Zhuang ST, Torbett BE
Interactions of HIV-1 Capsid with Host Factors and Their Implications for Developing Novel Therapeutics
VIRUSES-BASEL. 2021 MAR; 13 (3): Art. No. 417

6 6 Zheng J, Tse W, Lu B, Mwangi J, Rowe W, et al.
Intestinal Excretion is a Major Disposition Pathway of Lenacapavir in Rat and Dog
FASEB JOURNAL. 2021 MAY; 35

7 7 Piscaglia M, Cossu MV, Passerini M, Petri F, Gerbi M, et al.
Emerging drugs for the treatment of HIV/AIDS: a review of 2019/2020 phase II and III trials
EXPERT OPINION ON EMERGING DRUGS. 2021 JUL 3; 26 (3): 219-230

8 8 Begley R, Lutz J, Dvory--Sobol H, West S, Kawata K, et al.
Clinical evaluation of drug interactions with oral lenacapavir and probe drugs
HIV MEDICINE. 2021 AUG; 22: 25-26

9 9 Segal-Maurer S, Castagna A, Berhe M, Richmond GJ, Ruane PJ, et al.
Potent antiviral activity of lenacapavir in Phase 2/3 in heavily ART-experienced people with HIV
HIV MEDICINE. 2021 AUG; 22: 32-32

10 10 Margot N, VanderVeen L, Naik V, Chang S, Parvangada PC, et al.
Resistance analysis of long-acting lenacapavir in highly treatment-experienced people with HIV after 26 weeks of treatment

Search

Move to

Mark & Tag

Edit

Analyses index

Settings

Load...

Alt+M

Alt+S

Make graph

Select by

LCS x count

Limit: 30

Use mark

Node

Shape: circle

Size:

Scale * 1

Fixed 0.2

+ Node dista

Id placeme

inside node

Proximity: 1.

+ Arrowhead

Font sizes

Nodes: 10

Years: 10

Month: 8

Display

Draw links

Merge links

Gap years

of record

Months

Info

Legend brief

Size: window


Make graph

Export to file

format: Pajek

Restore default

11 [11](#) Stellbrink HJ, DeJesus E, Segal-Maurer S, Castagna A, Avihingsanon A, et al.
Subgroup efficacy analyses of long-acting subcutaneous lenacapavir in phase 2/3 in heavily treatment-experienced people with HIV (CAPELLA study)
HIV MEDICINE. 2021 OCT; 22: 125-126



Nodes: 30, Links: 24
LCS, top 30; Min: 2, Max: 25 (LCS scaled)

LCS GCS

- | | | |
|---|----|----|
| 1. 8 Begley R, 2021, HIV MED, V22, P25 | 4 | 5 |
| 2. 11 Stellbrink HJ, 2021, HIV MED, V22, P125 | 3 | 3 |
| 3. 18 Margot N, 2022, J ANTIMICROB CHEMOTH, V77, P989 | 25 | 30 |

Graphs Help Print graph Print text Keep graph PostScript (Letter pages: 4)

Make graph

Select by

LCS ▾ count

Limit: 15

Use 0 mark

Node

Shape: circle ▾

Size:

Scale * 1

Fixed 0.2

+ Node dista

Id placeme

inside node ▾

Proximity: 1.1

+ Arrowhead

Font sizes

Nodes: 15

Years: 10

Month: 8

Display

Draw links

Merge links

Gap years

of record

Months

Info

Legend brief

Size: window

Make graph

Export to file

format: Pajek

Restore default


2021

8

2022

2023

2024



149 149 Bekker LG, Das M, Karim Q
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women
NEW ENGL JOURNAL OF MEDICINE

149

Nodes: 15, Links: 10

LCS, top 15; Min: 4, Max: 25 (LCS scaled)

LCS GCS

- 8 Begley R, 2021, HIV MED, V22, P25
- 18 Margot N, 2022, J ANTIMICROB CHEMOTH, V77, P989
- 24 Marrazzo J, 2022, NEW ENGL J MED, V386, P1848
- 30 Paik J, 2022, DRUGS, V82, P1499
- 37 Margot NA, 2022, J INFECT DIS, V226, P1985
- 40 Nka AD, 2023, J ANTIMICROB CHEMOTH, V78, P272
- 41 Orkin C, 2023, LANCET HIV, V10, PE2
- 43 Lee NE, 2023, CURR OPIN INFECT DIS, V36, P15
- 59 Chatzidaki I, 2023, VALUE HEALTH, V26, P810
- 60 Tian J, 2023, EXPERT REV ANTI-INFECT THER, V21, P565

Record 149 View: Standard Edit

Author(s): Bekker LG (Bekker, Linda-Gail); Das M (Das, Moupani); Karim QA (Karim, Quarraisha Abdool); A Singh N (Singh, Nishanta); Singh Y (Singh, Yashna); Spooner E (Spooner, Elizabeth); Ward AM (Ward, Amy)

Title: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women

Source: NEW ENGL JOURNAL OF MEDICINE 391 (13): 1179-1192

Date: 2024 OCT 3

Document Type: Journal : Article

DOI: 10.1056/NEJMoa2407001 **IF:** 96.2 **Q1**

Language: English

LCR: 0 **CR:** 41 **LCS:** 20 **GCS:** 71 **OCS:**

Comment:

Address: [Bekker, Linda-Gail; Gill, Katherine; Nair, Gonasagrie; Singh, Yashna] Univ Cape Town, Desmond [Ward, Amy M.] Univ Cape Town, Dept Med, Vuka Res Clin, Cape Town, South Africa.

[Karim, Quarraisha Abdool] Univ KwaZulu Natal, Dept Epidemiol & Prevent, Ctr AIDS Programme Res South [Harkoo, Ishana; Mansoor, Leila E.; Moodley, Dhayendre; Naidoo, Megeshinee; Potloane, Disebo] Univ KwaZ [Jaggernath, Manjeetha] Univ Witwatersrand, Dept Obstet & Gynaecol, Wits Maternal Adolescent & Child Hlt

[Lebina, Limakatso] South African Med Res Council, Africa Hlth Res Inst, Durban, South Africa.

[Naicker, Vimla; Naidoo, Logashvari; Pillay, Suresha; Singh, Nishanta; Spooner, Elizabeth] South African Med [Ahmed, Khatija] Setshaba Res Ctr, Tshwane City, South Africa.

[Ahmed, Khatija] Univ Pretoria, Fac Hlth Sci, Sch Med, Dept Med Microbiol, Pretoria, South Africa.

[Zwane, Zwelethu] Aurum Inst, Pretoria Clin Res Site, Pretoria, South Africa.

[Batting, Joanne] Ndevana Community Res Site, Fdn Profess Dev, East London, South Africa.

[Malahleha, Moelo] Synergy Biomed Res Inst, East London, South Africa.

[Brumskine, William] Aurum Inst, Clin Res Div, Rustenburg, South Africa.

[Kotze, Philip] Qhakaza Mbokodo Res Clin, Ladysmith, South Africa.

[Kotze, Philip] La Verna Hosp, Ladysmith, South Africa.

[Louw, Cheryl E.] Madibeng Ctr Res, Brits, South Africa.

[Manentsa, Mmatsie] Univ Witwatersrand, Aurum Inst, Johannesburg, South Africa.

Graphs [Help](#)

[Print graph](#) [Print text](#) [Keep graph](#) [PostScript](#) (Letter pages: 3)

Make graph

Select by

LCS count

☒ Limit: 30

☐ Use 0 [mark](#)

Node

Shape: circle

Size:

☒ Scale * 15

☐ Fixed 0.2

+ Node dista

+ Id placeme

+ Arrowhead

Font sizes

Nodes: 35

Years: 40

Month: 8

Display

☒ Draw links

☐ Merge links

☐ Gap years

☐ # of record

☐ Months

☒ Info

☒ Legend brief


Size: window

Make graph

Export to file

format: Pajek

Restore default



Nodes: 30, Links: 203
LCS, top 30; Min: 207, Max: 864 (LCS scaled)

LCS GCS

- | | | |
|---|-----|-----|
| 1. 442 WRIGHT AD, 1970, Q J MED, V39, P1 | 354 | 480 |
| 2. 947 CLEMMONS DR, 1979, NEW ENGL J MED, V301, P1138 | 216 | 365 |
| 3. 979 ALEXANDER L, 1980, CLIN ENDOCRINOL, V12, P71 | 326 | 407 |
| 4. 1533 NABARRO JDN, 1987, CLIN ENDOCRINOL, V26, P481 | 358 | 493 |
| 5. 1582 BENGTTSSON BA, 1988, ACTA MED SCAND, V223, P327 | 334 | 456 |
| 6. 1763 MELMED S, 1990, NEW ENGL J MED, V322, P966 | 370 | 488 |
| 7. 2147 BATES AS, 1993, Q J MED, V86, P293 | 347 | 395 |

初步知识重构

近_____年来，关于_____研究方向，全球呈现_____趋势，其中较多的论文成果来自于_____（国家/地区）。发表相关论文较多的研究机构有_____。

主要从_____等领域对相关课题进行研究，_____等领域的研究可能会带来不一样的视角。

相关的研究成果主要发表在_____等期刊上，该领域_____等几位学者的科研产出较多。

影响力较高的几篇论文分别来自于_____（国家/地区）_____（研究机构）的_____（作者）。

近半年来，_____方向引起较多关注。

可选择_____（**综述文章**）作为快速了解该领域的切入点。

最新的研究显示该研究方向目前发展_____。

Graphs Help

Print graph

Print text

Keep graph

PostScript (Letter pages: 4)

Make graph

Select by

LCS count

Limit: 15

Use 0 mark

Node

Shape: circle

Size

Scale * 1

Fixed 0.2

+ Node dista

+ Id placeme

inside node

Proximity: 1.1

+ Arrowhead

Font sizes

Nodes: 15

Years: 10

Month: 8

Display

Draw links

Merge links

Gap years

of record

2021

8

2022

18

24

40

43

60

2023

Record 43

View: Standard

Edit

Author(s): Lee NE (Lee, Natalie E. E.); Sutherland RK (Sutherland, Rebecca K. K.)

Title: Lenacapavir and the novel HIV-1 capsid inhibitors: an emerging therapy in the management of HIV-1

Source: CURRENT OPINION IN INFECTIOUS DISEASES 36 (1): 15-19

Date: 2023 FEB

Document Type: Journal : Review

DOI: 10.1097/QCO.000000000000096

Language: English

LCR: 2 CR: 20 LCS: 6 GCS: 9 OCS:

Comment:

Address: [Lee, Natalie E. E.; Sutherland, Rebecca K. K.] Western Gen Hosp, Reg Infect Dis Unit, Clin Infect Dis Unit, Clin Infect Res Grp, Edinburgh EH4 2XU, Scotland

Reprint: Lee, NE (corresponding author), Western Gen Hosp, Reg Infect Dis Unit, Clin Infect Res Grp, Edinburgh

E-mail:

Author Keywords: lenacapavir treatment of virologically suppressed; naive; preexposure prophylaxis

KeyWords Plus:

Abstract: Purpose of reviewThe aim of this study was to summarize current evidence regarding lenacapavir. Lenacapavir is the first in class to have activity against multidrug resistant HIV-1 viral load. For these novel agents in a cohort of patients living with HIV-1 infection (PLWH) for whom multidrug resistance was still potentially attainable, offering some hope to PLWH with limited antiviral regimens available. Initial data suggest lenacapavir as an adjunctive agent in the management of PLWH with significant HIV-1 drug resistance.

Cited References:

[Anonymous], NCT04925752

[Anonymous], NCT04994509

[Anonymous], 2021, HIV DRUG RESISTANCE

[Anonymous], NCT05052996

[Anonymous], NCT04150000

Record 24

View: Standard

Edit

Author(s): Marrazzo J (Marrazzo, Jeanne)

Title: Lenacapavir for HIV-1-Potential Promise of a Long-Acting Antiretroviral Drug

Source: NEW ENGLAND JOURNAL OF MEDICINE 386 (19): 1848-1849

Date: 2022 MAY 12

Document Type: Journal : Editorial Material

DOI: 10.1056/NEJMe2204376

IF: 96.2 Q1

Language: English

LCR: 0 CR: 7 LCS: 5 GCS: 8 OCS:

Comment:

Address: [Marrazzo, Jeanne] Univ Alabama Birmingham, Birmingham, AL USA.

Reprint: Marrazzo, J (corresponding author), Univ Alabama Birmingham, Birmingham, AL USA.

E-mail:

Author Keywords:

KeyWords Plus:

Abstract: As we walk through the lobby of a modern clinic for the treatment of patients with human immunodeficiency virus (HIV), many patients already had resistance mutations to then-available nucleoside reverse transcriptase inhibitors, essentially offered functional monotherapy against a background of coinfection with hepatitis B virus (HBV).

Cited References:


[Anonymous], 2021, TECHNICAL REPORT HIV Antiretroviral Therapy Cohort Collaboration, 2017, Lancet HIV, V4, pe349, DOI 10.1016/S2352-3018(17)30060-0

National Institute of Child Health and Human Development National Institutes of Health, 2018, LIST REC TASK Force, 2018, J INFECTION, V18, P1362, DOI 10.1093/infdis/jix089


IF: 5.0 Q1

Segal-Maurer S, 2022, J INFECTION, V22, P1362, DOI 10.1093/infdis/jiab000


问题在哪儿?



问题在哪儿??



问题在哪儿? ? ? gigantism



信息梳理

研究趋势——InCites数据库



Clarivate

Web of Science™

Search

MENU

225 results from Web of Science

lenacapavir (Topic)

+ Add Keywords

Quick add keywords: < + lenacapavir + capsid inhibitor

225 Documents

You may also like...

Refine results

Export Refine

Search within results...

Quick Filters

☐ Highly Cited Papers

4

☐ Hot Papers

1

☐ Review Article

43

☐ Early Access

14

☐ Open Access

103

☐ Enriched Cited Refer...

75

- EndNote online
- EndNote desktop
- Add to my researcher profile
- Plain text file
- RefWorks
- RIS (other reference software)
- BibTeX
- Excel
- Tab delimited file
- Printable HTML file
- InCites
- Email
- Fast 5000
- More Export Options

English ▾

Products

Yin Wang ▾

Copy query link

program + cpsf6 + dapi >

Citation Report Create Alert

ance ▾ < 1 of 5 >

83 Citations

17 References

Related records ?

19 ?

225 results from Web of Science Core Collection for:

lenacapavir (Topic)

Copy query link

+ Add Keywords

Quick add keywords:

+ le

+ pepfar program

+ cpsf6

+ dapi

225 Documents

You may also like...

Refine results

Export Refine

Search within results...

Quick Filters

- ☐ Highly Cited Papers 4
- ☐ Hot Papers 1
- ☐ Review Article 43
- ☐ Early Access 14
- ☐ Open Access 103
- ☐ Enriched Cited Refer... 75

Save to InCites

Store up to 35 Web of Science datasets in InCites.

Dataset name

Web of Science lenacapavir 202503

Export Details

225 search results will be sent to InCites

Cancel

Export

Purpose of review This review summarizes available data for lenacapavir, an investigational first-in-class agent that disrupts functioning of HIV capsid protein across multiple steps in the viral ... [Show more](#)

[Free Full Text From Publisher](#) ...

83
Citations
17
References

Related records ?

19 ?

225 results from Web of Science Core Collection for:

lenacapavir (Topic)

+ Add Keywords

Quick add keywords:

< + lenacapavir

+ capsid inhibitor

+ gs-6207

+ sunlenca

+ pf74

+ pepfar progr

225 Documents

You may also like...

Analyze Results

Refine results

Export Refine

Search within results...

Quick Filters

- ☐ 🏆 Highly Cited Papers 4
- ☐ 🔥 Hot Papers 1
- ☐ 📄 Review Article 43
- ☐ ⌚ Early Access 14
- ☐ 🔒 Open Access 103
- ☐ 📌 Enriched Cited Refer... 75

✓ 50/225

Add To Marked List ▾

Export ▾

Sort by: Relevance ▾

< 1 of 5 >

✓ 1

📄

🔒

Lenacapavir: a first-in-class HIV-1 capsid inhibitor

Dvory-Sobol, H; Shaik, N; (...); Rhee, MS

Jan 2022 | CURRENT OPINION IN HIV AND AIDS 17 (1), pp.15-21

Purpose of review This review summarizes available data for **lenacapavir**, an investigational first-in-class agent that disrupts functioning of HIV capsid protein across multiple steps in the viral ... [Show more](#)

🔗 Free Full Text From Publisher ...

83

Citations

17

References

Related records ?

19 ?

Web of Science

Master Journal List

InCites Benchmarking & Analytics

Journal Citation Reports™

Research Horizon Navigator

Essential Science Indicators

Reference Manager

EndNote

EndNote Click



Analyze

Dig into the data.

Start from scratch, revisit recent analyses, or pick a popular use case to launch a starter analysis.

Start an analysis



Report

Gather your insights to present and share.

Create a custom report or revisit saved reports. Or, start with an overview report with analyses you can adjust as needed.

Explore reports




Organize

Keep tabs on multiple research questions and trends.


Organize your analyses, visuals, and reports into folders and dashboards that you can revisit.

Organize your projects


InCites——研究趋势之 国家发文趋势




InCites——研究趋势之 国家发文趋势



InCites——研究趋势之 研究人员发文数量



InCites——研究趋势之 研究人员影响力CNCI



趋势分析

专利——Derwent专利数据库



MENU

DOCUMENTS

RESEARCHERS

Search in Derwent Innovations Index ▾

DOCUMENTS

CITED PATENT SEARCH

COMPOUND SEARCH

Topic ▾

Example: Enzym*
lenacapavir

✕

+ Add row

+ Add date range

Advanced search

✕ Clear

🔍 Search



Recent searches

Last updated: Mar 19, 2025, 12:03 PM [Refresh list](#)

Latest alerts

Last updated: Mar 19, 2025, 12:03 PM

[Refresh list](#)

19?

27 results from Derwent Innovations Index for: lenacapavir (Topic) Copy query link

27 Documents

You may also like...

Analyze Results

Create Alert

Refine results

Export Refine

Search within topic...

Filter by Marked List ▾

Subject Areas ▴

- ☐ Chemistry 27
- ☐ Pharmacology Pharmacy 26
- ☐ Biotechnology Applied ... 13
- ☐ Polymer Science 11
- ☐ Agriculture 6

☐ 0/27

Add To Marked List

Export ▾

Relevance ▾

< 1 of 1 >

☐ 1


Preventing or treating HIV in patient involves administering to patient initiation dosage of **lenacapavir** derivative and maintenance dosages of **lenacapavir** derivative

WO2024220624-A1; US2024390349-A1; TW202444363-A

Inventors : BEGLEY R R; GERMAN P; (...); SINGH R

Assignee : GILEAD SCI INC

Derwent Primary Accession Number : 2024-B1787B

Download original ...

趋势分析

- 专利——Derwent专利数据库
- **核心词汇——Endnote**

EndNote X9 - [My EndNote Library]

File Edit References Group Tools Window Help

Show All Fields

My Library

- All References (200)
- Imported Referenc... (200)
- Sync Status...
- Recently Added (200)
- Unfiled (200)
- Trash (0)
- My Groups (0)
- Online Search (0)
- Find Full Text

Tools

- Search Library... Ctrl+F
- Spell Check Ctrl+Y
- Cite While You Write [CWYW] >
- Online Search...
- Format Paper >
- Change/Move/Copy Fields...
- Sync
- Open Term Lists >
- Define Term Lists... Ctrl+4
- Link Term Lists... Ctrl+3
- Sort Library...
- Recover Library...
- Find Broken Attachment Links...
- Library Summary...
- Subject Bibliography...**
- Manuscript Templates...

Quick Search

Search Whole Group ☐ Match Case ☐ Match Words

Reference Preview

No References Selected

	Rating	Journal	Last Upd...	R...
Current and future antiviral drug targets		Virology	2025/3/...	J...
SS-6207) Phenotypic Resistance in HIV Gag Cleavage Sit...		Antimicrobial Agent...	2025/3/...	J...
il Drug Development: Comprehensive Insights into Desi...		Journal of Microbiol...	2025/3/...	J...
low effective release antiretroviral therapies for treatm...		Advanced Drug Deli...	2025/3/...	J...
multiple classes induce loss of excitatory synapses betw...		Frontiers in Pharmac...	2025/3/...	J...
apavir Against Human Immunodeficiency Virus Type 2 (...)		Journal of Infectious ...	2025/3/...	J...
/-1 Capsid Inhibitor GSK878		Antimicrobial Agent...	2025/3/...	J...
Phase HPLC Method for the Simultaneous Determination...		Journal of Young Ph...	2025/3/...	J...
odies and long-acting antiretroviral drugs as treatment...		Current Opinion in H...	2025/3/...	J...
macapavir in Multidrug-Resistant HIV-1 Infection		New England Journa...	2025/3/...	J...
for HIV-1 ingress		Journal of Molecular...	2025/3/...	J...
for preventing mother-to-child HIV transmission		Microbiology and M...	2025/3/...	J...
avir Use in a Patient with Multidrug-Resistant HIV: The F...		Journal of Antimicro...	2025/3/...	J...
h HIV on the Long-Acting Combination of Lenacapavir a...		Yonsei Medical Jour...	2025/3/...	J...
living with HIV with detectable viral loads initiated the...		Open Forum Infectio...	2025/3/...	J...
Widely Available HIV Drugs Are Primed for Success i...		International Journal...	2025/3/...	J...
Scott, T. M.; Arnold, ... 2025 Cell-free assays reveal that the HIV-1 capsid protects reverse transcripts from cGA...		Pharmaceuticals	2025/3/...	J...
Begley, R.; Lutz, J.; D... 2021 Clinical evaluation of drug interactions with oral lenacapavir and probe drugs		Plos Pathogens	2025/3/...	J...
Antinori, A.; Castelli... 2022 Common adverse events in clinical studies of people using lenacapavir for HIV tr...		Hiv Medicine	2025/3/...	J...
Antinori, A.; Castelli... 2023 Common adverse events in clinical studies of people using lenacapavir for HIV tr...		Journal of the Intern...	2025/3/...	J...
Tao, K. M.; Zhou, J. R... 2024 Comprehensive database of HIV mutations selected during antiretroviral <i> in </i>...		Hiv Medicine	2025/3/...	J...
Hadia, R.; Patidar, S... 2024 A Comprehensive Review of the Safety and Efficacy of Lenacapavir in the Treatme...		Antiviral Research	2025/3/...	J...
Cluck, D. B.; Chastai... 2024 Consensus recommendations for the use of novel antiretrovirals in persons with ...		Journal of Young Ph...	2025/3/...	J...
Cluck, D. B.; Chastai... 2024 Consensus recommendations for the use of novel antiretrovirals in persons with ...		Pharmacotherapy	2025/3/...	J...
Sherman, E. M.; Ag... 2024 Consensus recommendations for use of long-acting antiretroviral medications in ...		Pharmacotherapy	2025/3/...	J...
Sherman, E. M.; Ag... 2024 Consensus recommendations for use of long-acting antiretroviral medications in ...		Pharmacotherapy	2025/3/...	J...
Kaftan, D.; Sharma, ... 2025 Cost thresholds for anticipated long-acting HIV pre-exposure prophylaxis produc...		Pharmacotherapy	2025/3/...	J...
Davey, D. J.; Jamies... 2024 Cost-effectiveness of lenacapavir for PrEP in Africa		Journal of the Intern...	2025/3/...	J...
Margot, N.; Pennetz... 2023 Cross-resistance to entry inhibitors and lenacapavir resistance through Week 52 i...		Lancet Hiv	2025/3/...	J...
Peng, Y.; Zeng, Y. J... 2023 Current drugs for HIV-1: from challenges to potential in HIV/AIDS		Antiviral Therapy	2025/3/...	J...
		Frontiers in Pharmac	2025/3/...	I...

Showing 200 of 200 references in Group. (All References: 200)

Layout

EndNote X9 - [My EndNote Library]

File Edit References Groups Tools Window Help

Show All Fields

Search

Options

Search Whole Group

☐ Match Case

☐ Match Words

Author

Contains

And

Year

Contains

And

Title

Contains

My Library

All References (200)

Imported Refer... (200)

Sync Status...

Recently Added (200)

Unfiled (200)

Trash (0)

My Groups (0)

Online Search (0)

Find Full Text

	Author	Year	Title	Rating	Journal	Last Upd...	R...
●	Nuwagaba, J.; Li, J. ...	2025	30 years of HIV therapy: Current and future antiretroviral drug targets		Virology	2025/3/...	J...
●	Margot, N.; Ram, R.; ...	2021	Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Sit...		Antimicrobial Agent...	2025/3/...	J...
●	Wang, H. Y.; Li, P. P.; ...	2024	Advancements in Antiviral Drug Development: Comprehensive Insights into Desi...		Journal of Microbiol...	2025/3/...	J...
●	Nayan, M. U.; Sillma...	2023	Advances in long-acting slow-release antiretroviral therapies for treatm...		Advanced Drug Deli...	2025/3/...	J...
●	McMullan, H. M.; Ga...	2024	Antiretroviral drugs from mul...		Frontiers in Pharmac...	2025/3/...	J...
●	Smith, R. A.; Raugi, ...	2024	Antiviral Activity of Lenacapa...		Journal of Infectious ...	2025/3/...	J...
●	Wang, C. F.; Huang, ...	2023	Antiviral Properties of HIV-1 C...		Antimicrobial Agent...	2025/3/...	J...
●	Madhavi, A.; Sriniva...	2024	Application of Reversed-Phas...		Journal of Young Ph...	2025/3/...	J...
●	Kuritzkes, D. R.	2023	Broadly neutralizing antibodi...		Current Opinion in H...	2025/3/...	J...
●	Segal-Maurer, S.; De...	2022	Capsid Inhibition with Lenac...		New England Journa...	2025/3/...	J...
●	Taylor, I. A.; Fassati, A.	2024	The capsid revolution		Journal of Molecular...	2025/3/...	J...
●	Jang, S.; Engelman, ...	2023	Capsid-host interactions for H...		Microbiology and M...	2025/3/...	J...
●	Hémar, V.; Bouchet, ...	2024	A case of lenacapavir use for p...		Journal of Antimicro...	2025/3/...	J...
●	Lee, Y. S.; Lee, K. H.; ...	2024	A Case Report of Lenacapavir...		Yonsei Medical Jour...	2025/3/...	J...
●	Gandhi, M.; Hill, L.; ...	2024	Case Series of People With HI...		Open Forum Infectio...	2025/3/...	J...
●	O'Neil, K. L.; Ching, ...	2025	Case series of two persons livi...		International Journal...	2025/3/...	J...
●	Kalemera, M. D.; Ma...	2024	Cell Culture Evaluation Hints...		Pharmaceuticals	2025/3/...	J...
●	Scott, T. M.; Arnold, ...	2025	Cell-free assays reveal that th...		Plos Pathogens	2025/3/...	J...
●	Begley, R.; Lutz, J.; D...	2021	Clinical evaluation of drug interactions with oral lenacapavir and probe drugs		Hiv Medicine	2025/3/...	J...
●	Antinori, A.; Castelli...	2022	Common adverse events in clinical studies of people using lenacapavir for HIV tr...		Journal of the Intern...	2025/3/...	J...
●	Antinori, A.; Castelli...	2023	Common adverse events in clinical studies of people using lenacapavir for HIV tr...		Hiv Medicine	2025/3/...	J...
●	Tao, K. M.; Zhou, J. R...	2024	Comprehensive database of HIV mutations selected during antiretroviral <i>in</i> <i>in</i>...		Antiviral Research	2025/3/...	J...
●	Hadia, R.; Patidar, S....	2024	A Comprehensive Review of the Safety and Efficacy of Lenacapavir in the Treatme...		Journal of Young Ph...	2025/3/...	J...
●	Cluck, D. B.; Chastai...	2024	Consensus recommendations for the use of novel antiretrovirals in persons with ...		Pharmacotherapy	2025/3/...	J...
●	Cluck, D. B.; Chastai...	2024	Consensus recommendations for the use of novel antiretrovirals in persons with ...		Pharmacotherapy	2025/3/...	J...
●	Sherman, E. M.; Ag...	2024	Consensus recommendations for use of long-acting antiretroviral medications in ...		Pharmacotherapy	2025/3/...	J...
●	Sherman, E. M.; Ag...	2024	Consensus recommendations for use of long-acting antiretroviral medications in ...		Pharmacotherapy	2025/3/...	J...
●	Kaftan, D.; Sharma, ...	2025	Cost thresholds for anticipated long-acting HIV pre-exposure prophylaxis produc...		Journal of the Intern...	2025/3/...	J...
●	Davey, D. J.; Jamies...	2024	Cost-effectiveness of lenacapavir for PrEP in Africa		Lancet Hiv	2025/3/...	J...
●	Margot, N.; Pennetz...	2023	Cross-resistance to entry inhibitors and lenacapavir resistance through Week 52 i...		Antiviral Therapy	2025/3/...	J...
●	Peng, Y.; Zeng, Y. L...	2023	Current drugs for HIV-1: from challenges to potential in HIV/AIDS		Frontiers in Pharmac...	2025/3/...	J...

Reference

Preview

No References Selected

Subject Fields

Selected Fields:

Custom 7

Custom 8

Accession Number

Call Number

Label

Keywords

Abstract

Notes

Research Notes

URL

File Attachments

Author Address

Figure

Caption

Access Date

Translated Author

Translated Title

☒ List each author separately

☐ In other fields, list each entry that is separated by slash, carriage return or line feed. (Keywords entries are always listed separately.)

OK

Cancel

Help

Showing 200 of 200 references in Group. (All References: 200)

Layout

EndNote X9 - [My EndNote Library]

File Edit References Groups Tools Window Help

Show All Fields

Quick Search

Hide Search Panel

My Library

All References (200)

Imported Refere... (200)

Sync Status...

Recently Added (200)

Unfiled (200)

Trash (0)

My Groups (0)

Online Search (0)

Find Full Text

Search Options

Search Whole Group

Match Case

Match Words

Author

Contains

And

Year

Contains

And

Title

Contains

	Author	Year	Title	Rating	Journal	Last Upd...	R...
●	Nuwagaba, J.; Li, J. ...	2025	30 years of HIV therapy: Current and future antiviral drug targets		Virology	2025/3/...	J...
●	Margot, N.; Ram, R.; ...	2021	Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Sit...		Antimicrobial Agent...	2025/3/...	J...
●	Wang, H. Y.; Li, P. P.; ...	2024	Advancements in Antiviral Drug Development: Comprehensive Insights into Desi...		Journal of Microbiol...	2025/3/...	J...
●	Nayan, M. U.; Sillma...	2023	Advances in long-acting slo		Advanced Drug Deli...	2025/3/...	J...
●	McMullan, H. M.; Ga...	2024	Antiretroviral drugs from m		Frontiers in Pharmac...	2025/3/...	J...
●	Smith, R. A.; Raugi, ...	2024	Antiviral Activity of Lenaca		Journal of Infectious ...	2025/3/...	J...
●	Wang, C. F.; Huang, ...	2023	Antiviral Properties of HIV-		Antimicrobial Agent...	2025/3/...	J...
●	Madhavi, A.; Sriniva...	2024	Application of Reversed-Ph		Journal of Young Ph...	2025/3/...	J...
●	Kuritzkes, D. R.	2023	Broadly neutralizing antibo		Current Opinion in H...	2025/3/...	J...
●	Segal-Maurer, S.; De...	2022	Capsid Inhibition with LENA		New England Journa...	2025/3/...	J...
●	Taylor, I. A.; Fassati, A.	2024	The capsid revolution		Journal of Molecular...	2025/3/...	J...
●	Jang, S.; Engelman, ...	2023	Capsid-host interactions fo		Microbiology and M...	2025/3/...	J...
●	Hémar, V.; Bouchet, ...	2024	A case of lenacapavir use fo		Journal of Antimicro...	2025/3/...	J...
●	Lee, Y. S.; Lee, K. H.; ...	2024	A Case Report of Lenacapav		Conseil Medical Jour...	2025/3/...	J...
●	Gandhi, M.; Hill, L.; ...	2024	Case Series of People With		Open Forum Infectio...	2025/3/...	J...
●	O'Neil, K. L.; Ching, ...	2025	Case series of two persons l		International Journal...	2025/3/...	J...
●	Kalemera, M. D.; Ma...	2024	Cell Culture Evaluation Hin		Pharmaceuticals	2025/3/...	J...
●	Scott, T. M.; Arnold, ...	2025	Cell-free assays reveal that		Plos Pathogens	2025/3/...	J...
●	Begley, R.; Lutz, J.; D...	2021	Clinical evaluation of drug		Hiv Medicine	2025/3/...	J...
●	Antinori, A.; Castelli...	2022	Common adverse events in clinical studies of people using lenacapavir for HIV tr...		Journal of the Intern...	2025/3/...	J...
●	Antinori, A.; Castelli...	2023	Common adverse events in clinical studies of people using lenacapavir for HIV tr...		Hiv Medicine	2025/3/...	J...
●	Tao, K. M.; Zhou, J. R...	2024	Comprehensive database of HIV mutations selected during antiretroviral <i>in</i> <i>in</i>...		Antiviral Research	2025/3/...	J...
●	Hadia, R.; Patidar, S....	2024	A Comprehensive Review of the Safety and Efficacy of Lenacapavir in the Treatme...		Journal of Young Ph...	2025/3/...	J...
●	Cluck, D. B.; Chastai...	2024	Consensus recommendations for the use of novel antiretrovirals in persons with ...		Pharmacotherapy	2025/3/...	J...
●	Cluck, D. B.; Chastai...	2024	Consensus recommendations for the use of novel antiretrovirals in persons with ...		Pharmacotherapy	2025/3/...	J...
●	Sherman, E. M.; Ag...	2024	Consensus recommendations for use of long-acting antiretroviral medications in ...		Pharmacotherapy	2025/3/...	J...
●	Sherman, E. M.; Ag...	2024	Consensus recommendations for use of long-acting antiretroviral medications in ...		Pharmacotherapy	2025/3/...	J...
●	Kaftan, D.; Sharma, ...	2025	Cost thresholds for anticipated long-acting HIV pre-exposure prophylaxis produc...		Journal of the Intern...	2025/3/...	J...
●	Davey, D. J.; Jamies...	2024	Cost-effectiveness of lenacapavir for PrEP in Africa		Lancet Hiv	2025/3/...	J...
●	Margot, N.; Pennetz...	2023	Cross-resistance to entry inhibitors and lenacapavir resistance through Week 52 i...		Antiviral Therapy	2025/3/...	J...
●	Peng, Y.; Zeng, Y. L...	2023	Current drugs for HIV-1: from challenges to potential in HIV/AIDS		Frontiers in Pharmac...	2025/3/...	J...

Showing 200 of 200 references in Group. (All References: 200)

Layout

Subject Terms

Selected Terms	# Records
LENACAPAVIR	69
HIV	47
HIV-1	25
cabotegravir	24
INFECTION	23
ANTIRETROVIRAL THERAPY	23
capsid	22
EFFICACY	17
THERAPY	13
PREEXPOSURE PROPHYLAXIS	13
ADULTS	12
prevention	12
long-acting	12
DRUG-RESISTANCE	12
RILPIVIRINE	11

0 Term(s) Selected

Select All

Clear Selection(s)

OK

Cancel

Help

趋势分析

- 专利——Derwent专利数据库
- 核心词汇——Endnote
- 基金——**Web of Science**

>I
MENU[Search](#) > Analyze Results: lenacapavir (Topic)**Analyze Results**

225 publications selected from Web of Science Core Collection

Funding Agencies ▾



Sort by:

Results count ▾

Show:

25 ▾

Minimum record count:

1

Visualization:

TreeMap Chart ▾

Number of results:

10 ▾

DOWNLOAD

42
NATIONAL INSTITUTES OF HEALTH NIH USA26
GILEAD SCIENCES18
NIH NATIONAL
INSTITUTE OF
ALLERGY INFECTIOUS
DISEASES NIAID

19 ?

❁找同行

同主题会议



>|
MENU[Search](#) > Analyze Results: lenacapavir (Topic)**Analyze Results**

225 publications selected from Web of Science Core Collection

Conference Titles ▾

Sort by:

Results count ▾

Show:

25 ▾

Minimum record count:

1

Visualization:

TreeMap Chart

ANNUAL MEETING OF THE AMERICAN
SOCIETY FOR CLINICAL PHARMACOLOGY AND
THERAPEUTICS ASCPT1
records

View Records

DOWNLOAD

1
ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CLINICAL
PHARMACOLOGY AND THERAPEUTICS ASCPT1
EXPERIMENTAL BIOLOGY MEETING

19 ?

❁找同行

同地址检索



MENU



DOCUMENTS

RESEARCHERS

Search in: Web of Science Core Collection ▾ Editions: All ▾

DOCUMENTS

CITED REFERENCES

STRUCTURE

Topic ▾

Example: oil spill* mediterranean
lenacapavir

And ▾

Address ▾

Example: Yale Univ SAME hosp
shanghai

+ Add row

+ Add date range

Advanced search

× Clear

Search

[Search](#) > [Analyze Results: lenacapavi...](#) > [Results for lenacapavir \(To...](#) > [Results for lenacapavir \(To...](#) >

Results for lenacapavir (Topic) AND shanghai (Address)

2 results from Web of Science Core Collection for:

lenacapavir (Topic) and shanghai (Address)

[Copy query link](#)[+ Add Keywords](#)2 Documents[You may also like...](#)[Analyze Results](#)[Citation Report](#)[Create Alert](#)

Refine results

[Export Refine](#)

Search within results...

Quick Filters

- ☐ Review Article 1
- ☐ Open Access 2

☐ 0/2[Add To Marked List](#)[Export ▾](#)

Relevance ▾

< 1 of 1 >

☐ 1

Lack of Resistance Mutations to the Novel HIV-1 Capsid Inhibitor
Lenacapavir Among People Living with HIV in Guangdong, China

Lin, YQ; Ling, XM; (...); Lan, Y

2024 | INFECTION AND DRUG RESISTANCE 17, pp.4271-4277

Background: The capsid inhibitor (CAI) **lenacapavir** (LEN) was approved for use in 2022, yet there are few reports about its drug resistance mutations (DRMs) and sensitivity. Purpose: To delineate th [Show more](#)

21

References

信息扩充

➤ 关键词——**HistCite (Pro)**

File	Analyses	View	Tools	HistCite™				
Unfiltered	Records	199		Grand Totals: LCS 230, GCS 1423, CR 8341				
List of	Authors	1158		Collection span: 2020 - 2025				
Records	Journals	103						
Yearly	Cited References	5503						
<	Words	719						
#			Date / Author / Journal	LCS	GCS	LCR	CR	
21	Yearly output		2022					
22	Document Type		retroviral therapy in low-income and middle-income countries	1	12	0	30	
22	Language		2022 MAY; 17 (3): 127-134					
22	Institution		YC, et al.	3	9	0	20	
22	Institution with Subdi		destroy the virus					
23	Country		MAY; 14 (9): 605-607					
23			Castagna A, Richmond GJ, et al.	0	149	0	19	
24			Lenacapavir for HIV-1-Potential Promise of a Long-Acting Antiretroviral Drug	5	8	0	7	
24			NEW ENGLAND JOURNAL OF MEDICINE. 2022 MAY 12; 386 (19): 1848-1849					
25			Novel and Investigational HIV Therapies for Treatment and Prevention: Focus on Cabotegravir, Islatravir, and Lenacapavir	0	7	0	35	
25			CURRENT INFECTIOUS DISEASE REPORTS. 2022 JUL; 24 (7): 89-96					
26			The future of long-acting agents for preexposure prophylaxis	3	17	0	34	
26			CURRENT OPINION IN HIV AND AIDS. 2022 JUL; 17 (4): 192-198					
27			How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?	3	18	0	98	
27			CURRENT OPINION IN HIV AND AIDS. 2022 JUL; 17 (4): 213-221					
28			Pharmacokinetics of a Simplified Subcutaneous Lenacapavir Regimen versus Phase 2/3 Regimen	0	0	0	0	
28			JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 2022 AUG; 25: 124-124					
29			Simulations for Once Weekly Dosing of Oral Lenacapavir	0	0	0	0	
29			JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 2022 AUG; 25: 125-125					
30			Lenacapavir: First Approval	17	40	2	19	
30			DRUGS. 2022 SEP; 82 (14): 1499-1504					
#			Date / Author / Journal	LCS	GCS	LCR	CR	
31			Week 52 subgroup efficacy analyses of long-acting subcutaneous lenacapavir in phase II/III in heavily treatment-experienced people with multidrug-resistant HIV (CAPELLA study)	0	0	0	0	
31			JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 2022 OCT; 25: 37-38					
32			Common adverse events in clinical studies of people using lenacapavir for HIV treatment	0	0	0	1	
32			JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 2022 OCT; 25: 38-39					
33			Phenotypic analyses of clinical isolates with capsid substitutions observed in people with HIV (PWHIV) treated with lenacapavir	0	0	0	0	
33			JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 2022 OCT; 25: 197-197					

Untitled Collection

Grand Totals: LCS 230, GCS 1423, CR 8341
Collection span: 2020 - 2025

Word(i) List (719) Word count: 2124, All words count: 2963
Records: 199, Authors: 1158, Journals: 103, Cited References: 5503, Words: 719
[Yearly output](#) | [Document type](#) | [Language](#) | [Institution](#) | [Institution with Subdivision](#) | [Country](#)

|< << < > >> >|

#	Word	Recs	TLCS	TGCS
1	HIV	142	161	1022
2	LENACAPAVIR	119	208	781
3	CAPSID	49	94	608
4	TREATMENT	42	59	139
5	LONG	34	35	160
6	ACTING	33	35	160
7	PEOPLE	29	36	77
8	PREVENTION	23	26	170
9	RESISTANT	23	58	244
10	INHIBITOR	22	72	256
11	RESISTANCE	22	67	226
12	DRUG	21	29	174
13	NOVEL	19	79	196
14	ANTIRETROVIRAL	17	19	184
15	EXPERIENCED	17	31	52
16	MULTIDRUG	17	46	224
17	CLINICAL	15	35	135
18	EFFICACY	14	51	73
19	HEAVILY	14	7	15
20	INFECTION	13	10	222
21	VIRUS	13	44	102
22	YEARLY	13	25	89
23	TWICE	12	25	89
24	PHASE	11	27	45
25	PROPHYLAXIS	11	8	76
26	VIRAL	11	10	79
27	DRUGS	10	4	29
28	FIRST	10	43	167
29	INJECTABLE	10	13	54
30	THERAPY	10	12	134
#	Word	Recs	TLCS	TGCS

信息扩充

➤ 关键词——HistCite、**Endnote**

- My Library
- All References (200)
 - Imported Reference (200)
 - Sync Status...
 - Recently Added (200)
 - Unfiled (200)
 - Trash (0)
 - My Groups (0)
 - Online Search (0)
 - Find Full Text

Search Options

Author Contains

And Year Contains

And Title Contains

Author	Year	Title	Rating	Journal	Last Upd...	R...
Nuwagaba, J.; Li, J. ...	2025	30 years of HIV therapy: Current and future antiviral drug targets		Virology	2025/3/...	J...
Margot, N.; Ram, R.; ...	2021	Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Sit...		Antimicrobial Agent...	2025/3/...	J...
Wang, H. Y.; Li, P. P.; ...	2024	Advancements in Antiviral Drug Development: Comprehensive Insights into Desi...		Journal of Microbiol...	2025/3/...	J...
Nayan, M. U.; Sillma...	2023	Advances in long-acting slow effective release antiretroviral therapies for treatm...		Advanced Drug Deli...	2025/3/...	J...
McMullan, H. M.; Ga...	2024	Antiretroviral drugs from mul...		Frontiers in Pharmac...	2025/3/...	J...
Smith, R. A.; Raugi, ...	2024	Antiviral Activity of Lenacapa...		Journal of Infectious ...	2025/3/...	J...
Wang, C. F.; Huang, ...	2023	Antiviral Properties of HIV-1 C...		Antimicrobial Agent...	2025/3/...	J...
Madhavi, A.; Sriniva...	2024	Application of Reversed-Phase...		Journal of Young Ph...	2025/3/...	J...
Kuritzkes, D. R.	2023	Broadly neutralizing antibody...		Current Opinion in H...	2025/3/...	J...
Segal-Maurer, S.; De...	2022	Capsid Inhibition with Lenaca...		New England Journa...	2025/3/...	J...
Taylor, I. A.; Fassati, A.	2024	The capsid revolution		Journal of Molecular...	2025/3/...	J...
Jang, S.; Engelman, ...	2023	Capsid-host interactions for H...		Microbiology and M...	2025/3/...	J...
Hémar, V.; Bouchet, ...	2024	A case of lenacapavir use for p...		Journal of Antimicro...	2025/3/...	J...
Lee, Y. S.; Lee, K. H.; ...	2024	A Case Report of Lenacapavir		Yonsei Medical Jour...	2025/3/...	J...
Gandhi, M.; Hill, L.; ...	2024	Case Series of People With HIV		Open Forum Infectio...	2025/3/...	J...
O'Neil, K. L.; Ching, ...	2025	Case series of two persons livi...		International Journal...	2025/3/...	J...
Kalemera, M. D.; Ma...	2024	Cell Culture Evaluation Hints		Pharmaceuticals	2025/3/...	J...
Scott, T. M.; Arnold, ...	2025	Cell-free assays reveal that th...		Plos Pathogens	2025/3/...	J...
Begley, R.; Lutz, J.; D...	2021	Clinical evaluation of drug interactions with oral lenacapavir and probe drugs		Hiv Medicine	2025/3/...	J...
Antinori, A.; Castelli...	2022	Common adverse events in clinical studies of people using lenacapavir for HIV tr...		Journal of the Intern...	2025/3/...	J...
Antinori, A.; Castelli...	2023	Common adverse events in clinical studies of people using lenacapavir for HIV tr...		Hiv Medicine	2025/3/...	J...
Tao, K. M.; Zhou, J. R...	2024	Comprehensive database of HIV mutations selected during antiretroviral <i> in </i>...		Antiviral Research	2025/3/...	J...
Hadia, R.; Patidar, S...	2024	A Comprehensive Review of the Safety and Efficacy of Lenacapavir in the Treatme...		Journal of Young Ph...	2025/3/...	J...
Cluck, D. B.; Chastai...	2024	Consensus recommendations for the use of novel antiretrovirals in persons with ...		Pharmacotherapy	2025/3/...	J...
Cluck, D. B.; Chastai...	2024	Consensus recommendations for the use of novel antiretrovirals in persons with ...		Pharmacotherapy	2025/3/...	J...
Sherman, E. M.; Ag...	2024	Consensus recommendations for use of long-acting antiretroviral medications in ...		Pharmacotherapy	2025/3/...	J...
Sherman, E. M.; Ag...	2024	Consensus recommendations for use of long-acting antiretroviral medications in ...		Pharmacotherapy	2025/3/...	J...
Kaftan, D.; Sharma, ...	2025	Cost thresholds for anticipated long-acting HIV pre-exposure prophylaxis produc...		Journal of the Intern...	2025/3/...	J...
Davey, D. J.; Jamies...	2024	Cost-effectiveness of lenacapavir for PrEP in Africa		Lancet Hiv	2025/3/...	J...
Margot, N.; Pennetz...	2023	Cross-resistance to entry inhibitors and lenacapavir resistance through Week 52 i...		Antiviral Therapy	2025/3/...	J...
Peng, Y.; Zeng, Y. J...	2023	Current drugs for HIV-1: from challenges to potential in HIV/AIDS		Frontiers in Pharmac...	2025/3/...	J...

Subject Fields

Selected Fields:

- Custom 7
- Custom 8
- Accession Number
- Call Number
- Label
- Keywords
- Abstract
- Notes
- Research Notes
- URL
- File Attachments
- Author Address
- Figure
- Caption
- Access Date
- Translated Author
- Translated Title

☒ List each author separately

☐ In other fields, list each entry that is separated by slash, carriage return or line feed. (Keywords entries are always listed separately.)

OK Cancel Help

Reference Preview

No References Selected

信息扩充

➤ 关键词——HistCite、Endnote、**ESI**



Top Papers by Research Fronts

Results List

Research Fronts

Filter Results By

Changing the filter
removes all current filters.

Add Filter »

Search Research

Attributes

Research Fields »

Research Fronts »

Include Results For


Top Papers

Clear

Save Criteria

Map View by Top / Hot / Highly Cited Papers

Hide Visualization —



0 82

Report View by Selection

Customize

Total:	Research Fronts	Top Papers	Mea Year
13830			
1	WANGS FRACIAL VARIATIONAL PRINCIPLE; FRACTAL VARIATIONAL THEORY; FRACTAL VIBRATION MODEL; FRACTAL TODA OSCILLATOR	50	20
1	NEW SHORT-WAVELENGTH NONLINEAR OPTICAL FLUORIDE MATERIAL FEATURING UNPRECEDENTED POLAR C/S-ZR ₆ F ₃₄ 110-CLUSTERS; FIRST UV NONLINEAR OPTICAL SELENITE MATERIAL; UNEARTHING SUPERIOR INORGANIC UV SECOND-ORDER NONLINEAR OPTICAL MATERIALS; DEEP-ULTRAVIOLET NONLINEAR OPTICAL MATERIALS; UV NONLINEAR	50	20



Top Papers by Research Fronts

Results List

Research Fronts

Filter Results By

Changing the filter field
removes all current
filters.

Add Filter »

lenacapavir

There are no results to display

Include Results For


Top Papers

Clear

Save Criteria

Map View by Top / Hot / Highly Cited Papers

Hide Visualization —



0 82

Report View by Selection

Customize

Total:
13830

Research Fronts

Top Papers

Mea
Year

1

WANGS FRACTAL VARIATIONAL PRINCIPLE;
FRACTAL VARIATIONAL PRINCIPLE; FRACTAL
VARIATIONAL THEORY; FRACTAL VIBRATION
MODEL; FRACTAL TODA OSCILLATOR

50

20

1

NEW SHORT-WAVELENGTH NONLINEAR OPTICAL
FLUORIDE MATERIAL FEATURING
UNPRECEDENTED POLAR C/S-ZR₆F₃₄110-
CLUSTERS; FIRST UV NONLINEAR OPTICAL
SELENITE MATERIAL; UNEARTHING SUPERIOR
INORGANIC UV SECOND-ORDER NONLINEAR
OPTICAL MATERIALS; DEEP-ULTRAVIOLET
NONLINEAR OPTICAL MATERIAL; S-TRIM NONLINEAR

50

20



Top Papers by Research Fronts

Results List

Research Fronts

Filter Results By


Changing the filter field
removes all current
filters.

Add Filter »

HIV
COVID-19 PANDEMIC;
FLUORESCENCE DUA
FRACTIONAL ORDER I
HIV CAPSID PROTEIN;
HIV INFECTION US PR
HIV PREEXPOSURE PI
HIV TESTING;UNIVERS
HIV-1 RESERVOIR CEL

Map View by Top / Hot / Highly Cited Papers

Hide Visualization —



0 82

Report View by Selection

Customize

Total:	Research Fronts	Top Papers	Mea Year
13830			
1	WANGS FRACTAL VARIATIONAL PRINCIPLE; FRACTAL VARIATIONAL PRINCIPLE; FRACTAL VARIATIONAL THEORY; FRACTAL VIBRATION MODEL; FRACTAL TODA OSCILLATOR	50	20
1	NEW SHORT-WAVELENGTH NONLINEAR OPTICAL FLUORIDE MATERIAL; FEATURING UNPRECEDENTED POLAR C/S-ZR ₆ F ₃₄ 110- CLUSTERS; FIRST UV NONLINEAR OPTICAL SELENITE MATERIAL; UNEARTHING SUPERIOR INORGANIC UV SECOND-ORDER NONLINEAR OPTICAL MATERIALS; DEEP-ULTRAVIOLET NONLINEAR OPTICAL MATERIAL; S-TRIM NONLINEAR	50	20



Top Papers by Research Fronts

Results List

Research Fronts

Filter Results By

Changing the filter field
removes all current
filters.

Add Filter

x HIV CAPSID
PROTEIN;CAPSID
INHIBITION;MULTIDRU
RESISTANT HIV-1
INFECTION;LONG-
ACTING SMALL
MOLECULE;CLINICAL
TARGETING

Include Results For


Top Papers

Clear

Save Criteria

Map View by Top / Hot / Highly Cited Papers

Hide Visualization



Report View by Selection

Customize

Total:	Research Fronts	Top Papers	Mea Year
1			
1	HIV CAPSID PROTEIN;CAPSID INHIBITION;MULTIDRUG-RESISTANT HIV-1 INFECTION;LONG-ACTING SMALL MOLECULE;CLINICAL TARGETING	2	20



Papers by Research Field

Citation Trends

Documents

Filter Results By ⓘ

Add Filter »

× HIV CAPSID
PROTEIN; CAPSID
INHIBITION;
MULTIDRUG-
RESISTANT HIV-1
INFECTION; LONG-
ACTING SMALL
MOLECULE;
CLINICAL
TARGETING

Include Results For

Top Papers

Clear

Save Criteria

Sort By Citations

Customize Documents

1 - 2 of 2

1 CLINICAL TARGETING OF HIV CAPSID PROTEIN WITH A LONG-ACTING SMALL MOLECULE

By: LINK, JO; RHEE, MS; TSE, WC; et.al

Source: NATURE 584 (7822): 614-+ AUG 27 2020

Research Fields: MICROBIOLOGY

Times Cited: 327



Research Front

2 CAPSID INHIBITION WITH LENACAPAVIR IN MULTIDRUG-RESISTANT HIV-1 INFECTION

By: SEGAL-MAURER, S; DEJESUS, E; STELLBRINK, HJ; et.al

Source: NEW ENGLAND JOURNAL OF MEDICINE 386 (19): 1793-1803 MAY 12 2022

Research Fields: CLINICAL MEDICINE

Times Cited: 126



Research Front

信息扩充

- 关键词——HistCite、Endnote、**ESI**
- 引文——**ESI**



Papers by Research Field

Citation Trends

Documents

Filter Results By

Add Filter »

× HIV CAPSID PROTEIN; CAPSID INHIBITION; MULTIDRUG-RESISTANT HIV-1 INFECTION; LONG-ACTING SMALL MOLECULE; CLINICAL TARGETING

Include Results For

Top Papers

Clear

Save Criteria

Sort By Citations

Customize Documents

1 - 2 of 2

1 CLINICAL TARGETING OF HIV CAPSID PROTEIN WITH A LONG-ACTING SMALL MOLECULE

By: LINK, JO; RHEE, MS; TSE, WC; et.al
Source: NATURE 584 (7822): 614-+ AUG 27 2020
Research Fields: MICROBIOLOGY

Times Cited: 327
Research Front

2 CAPSID INHIBITION WITH LENACAPAVIR IN MULTIDRUG-RESISTANT HIV-1 INFECTION

By: SEGAL-MAURER, S; DEJESUS, E; STELLBRINK, HJ; et.al
Source: NEW ENGLAND JOURNAL OF MEDICINE 386 (19): 1793-1803 MAY 12 2022
Research Fields: CLINICAL MEDICINE

Times Cited: 126
Research Front

图书
连续出版物
会议论文
专利
.....



Web of Science
InCites
ESI

Endnote/NE

HistCite
.....

拓展





Search

lenacapavir



ALL

NEWS

PAGE

STORIES

VIDEO

DOCUMENTS

84 search results for 'lenacapavir'

Sort By: **Relevance** ▼

Gilead Submits Marketing Authorization Applications to European Medicines Agency for Twice-Yearly **Lenacapavir** for HIV Prevention

<https://www.gilead.com/company/company-statements/2025/gilead-submits-marketing-authorization-applications-to-european-medicines-agency-for-twice-yearly-lenacapavir-for-hiv-prevention>

News

Updated Statement on Access Planning in High-Incidence, Resource-Limited Countries for **Lenacapavir** for HIV Prevention

<https://www.gilead.com/company/company-statements/2024/updated-statement-on-access-planning-in-high-incidence-resource-limited-countries-for-lenacapavir-for-hiv-prevention>

News

Gilead Submits New Drug Application to U.S. Food and Drug



审定公布名词数据库：4753 条

全部年度 10条/页 收起

衣壳蛋白

英文名：[capsid protein]

公布年度：2019

衣壳蛋白

定义：由大量相同的蛋白亚单位构建成的三维结构。对保护病毒的遗传信息及病毒遗传信息的复制有着极其重要的作用。

英文：[capsid protein]

学科：「感染病学_病原体感染_病毒感染」

来源：感染病学名词

[点击, 查看更多 >](#)

★收藏 <分享 纠错

抑制剂

英文名：inhibitor

公布年度：2023

抑制剂

定义：降低或阻滞微生物或酶特定基团活性的物质。

英文：inhibitor

学科：「化工9_肥料」

来源：化工9名词

[点击, 查看更多 >](#)

★收藏 <分享 纠错

抑制剂

英文名：[inhibitor]

公布年度：2020

抑制剂

英文：[inhibitor]

学科：「生理学_细胞生理学」

来源：生理学名词

[点击, 查看更多 >](#)

★收藏 <分享 纠错



学术派

信息扩充

- 关键词——Endnote、ESI、HistCite
- 引文——ESI
- **不同视角？**

Analyze Results

225 publications selected from Web of Science Core Collection

Web of Science Index



Sort by:

Results count

Show:

25

Minimum record count:

1

Visualization:

Hide Visualiza...

Number of results:

10



DOWNLOAD

Showing 25 out of 5 entries

Select All



Field:

Web of Science Index

Record Count

% of 225



Science Citation Index Expanded (SCI-EXPANDED)

209

92.889%



Emerging Sources Citation Index (ESCI)

15

6.667%



Social Sciences Citation Index (SSCI)

8

3.556%

免疫/12.1“世界艾滋病”,三个内容: 我国情况, 指南更新, 为何难治

后发生了感染; 今年7月, 长效预防方案lenacapavir (每半年注射一次) 发表了最新的研究结果, 2000多名受试者中达到了百分百保护。 “其现在治愈和治疗已经逐渐融合, 治愈的核心是...

临床检验 · 280 浏览 · 2024-12-01

微生物免疫交叉|亚冬会开幕式, 讲一讲HIV“疫苗”

(2.7) 亚冬会开幕了, 咱们讲一讲一个奇妙的“疫苗”美国吉利德科学 (Gilead Sciences) 开发的一款长效艾滋病“疫苗”, 来那帕韦 (Lenacapavir)。你可能注意到, 这里我们讲到来那帕

临床检验 · 70 浏览 · 2025-02-07

亚冬开幕式, 讲一讲特殊的HIV“疫苗”

(2.7) 亚冬会开幕了, 咱们讲一讲一个奇妙的“疫苗”美国吉利德科学 (Gilead Sciences) 开发的一款长效艾滋病“疫苗”, 来那帕韦 (Lenacapavir)。你可能注意到, 这里我们讲到来那帕

公共卫生 · 4 浏览 · 2025-02-07

多重耐药HIV-1感染新药! FDA批准Sunlenca(lenacapavir)

Gilead公司近日宣布, 其药物Sunlenca(lenacapavir)与其他抗逆转录病毒药物(ARV)联合使用已获得美国(FDA)的批准, 用于治疗在接受过大量治疗的多重耐药HIV-1感染成人中

新药信息 · 1613 浏览 · 2022-12-26

6个月一次长效HIV疗法lenacapavir(GS-6207)在美提交上市申请

香港济民药业 讯: 吉利德 (Gilead) 近日宣布, 已向美国食品和药物管理局 (FDA) 提交了lenacapavir (GS-6207) 的新药申请 (NDA), 该药是一种长效HIV-1衣壳抑制剂, 用于治疗

新药信息 · 734 浏览 · 2021-07-01

相关版块



新药信息

去版块

67.9万内容 · 69.6万关注

相关产品

更多>



Lenacapavir



MedChemExpress LLC

★★★★★



Lenacapavir



广州威佳科技有限公司

★★★★★



lenacapavir, 2189684-44-2, Moligand™, 阿拉丁
上海阿拉丁生化科技股份有限公司

★★★★★



Lenacapavir



TargetMol中国

★★★★★

[新闻](#)[hao123](#)[地图](#)[贴吧](#)[视频](#)[图片](#)[网盘](#)[更多](#)

[设置](#)

[登录](#)

Bai

du

百度

百度一下

搜索设置

高级搜索

×

搜索结果:

包含全部关键词

包含完整关键词

包含任意关键词

不包括关键词

时间: 限定要搜索的网页的时间是

时间不限

文档格式: 搜索网页格式是

所有网页和文件

关键词位置: 查询关键词位于

☒ 网页任何地方

☐ 仅网页标题中

☐ 仅URL中

站内搜索: 限定要搜索指定的网站是

例如: baidu.com

高级搜索

🔄

📱

[关于百度](#)[About Baidu](#)[使用百度前必读](#)[帮助中心](#)[企业推广](#)[京公网安备11000002000001号](#)[京ICP证030173号](#)[互联网新闻信息服务许可证11220180008](#)[网络文化经营许可证: 京网文〔2023〕1034-029号](#)[信息网络传播视听节目许可证0110516](#)[互联网宗教信息服务许可证编号: 京\(2022\) 0000043](#)

📶

⤴

To Be Continued

